


(±)-Huperzine A

Cat. No.:	HY-17388		
CAS No.:	120786-18-7		
Molecular Formula:	C ₁₅ H ₁₈ N ₂ O		
Molecular Weight:	242.32		
Target:	AChE		
Pathway:	Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (206.34 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.1268 mL	20.6339 mL	41.2677 mL
	5 mM	0.8254 mL	4.1268 mL	8.2535 mL
	10 mM	0.4127 mL	2.0634 mL	4.1268 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(±)-Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD). IC50 value: Target: AChE(±)-Huperzine A exhibited protective effects against d-gal-induced hepatotoxicity and inflamm-aging by inhibiting AChE activity and via the activation of the cholinergic anti-inflammatory pathway. The (±)-Huperzine A mechanism might be involved in the inhibition of DAMPs-mediated NF-κB nuclear localization and activation. (±)-Huperzine A is a potential therapeutic agent for Alzheimer's disease.

REFERENCES

- [1]. Burshtein G, Friedman M, Greenberg S, Hoffman A. Transepithelial Transport of a Natural Cholinesterase Inhibitor, Huperzine A, along the Gastrointestinal Tract: the Role of Ionization on Absorption Mechanism. *Planta Med.* 2013 Jan 23.
- [2]. Ruan Q, Liu F, Gao Z, et al. The anti-inflamm-aging and hepatoprotective effects of huperzine A in d-galactose-treated rats. *Mech Ageing Dev.* 2013 Jan 8. pii: S0047-6374(12)00182-0.
- [3]. Zhang HY. New insights into huperzine A for the treatment of Alzheimer's disease. *Acta Pharmacol Sin.* 2012 Sep;33(9):1170-5.
- [4]. Wang J, Zhang HY, Tang XC. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. *J Neurosci Res.* 2010 Mar;88(4):807-15. doi: 10.1002/jnr.22237.
- [5]. Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. *Neurosci Lett.* 2010 Feb 5;470(1):6-9. doi: 10.1016/j.neulet.2009.12.033.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA